Novartis announced today the early termination of the ALTITUDE trial, which was testing the effect of the direct renin inhibitor aliskiren (Rasilez, Tekturna) in type 2 diabetics at high risk for cardiovascular and renal events.
In addition to his many papers exploring the basic science of the renin-angiotensin system, Matsubara was the chief investigator of the KYOTO HEART Study, a randomized, open-labeled trial studying the add-on effect of valsartan to conventional therapy in high-risk hypertension.